Inflammation

Pediatric patients with atopic dermatitis (AD) often vary in disease severity and it can be difficult to assess how much of a topical therapy is needed, said Lawrence F. Eichenfield, MD, chief of pediatric and adolescent dermatology at Rady Children's Hospital-San Diego.

A handful of systemic therapies can be prescribed off label to effectively treat atopic dermatitis (AD), but investigators said a biologic option may be best for many patients.

Highlighting the latest inflammation-related news reported across MJH Life Sciences™.

A panel of health care professionals reviewed published literature to develop a recommendation guide to advise providers on best practices when considering vaccinations for children with atopic dermatitis (AD) on dupilumab.

Patients with atopic dermatitis (AD) benefit from extensive patient education. A new report suggests group-based sessions are preferred to individual educational sessions or fun activities.

Existing research has focused on skin symptoms, but a new study looks for alterations in the blood associated with moderate-to-severe atopic dermatitis.

A new report shows work-related quality of life in general—and also in terms of physical and mental/emotional health—improved when patients began treatment for atopic dermatitis.

Now that racial and ethnic disparities of atopic dermatitis prevalence among children have been confirmed, the next step in research will be to discover the reasons why those disparities exist, said Jonathan Silverberg, MD, PhD, MPH.

Children with severe atopic dermatitis, in particular, were less likely than a control group to complete education at all levels, from basic compulsory education to postgraduate education.

In order to properly help patients manage their disease, it is critical for clinicians to recognize the differences in prevalence, severity, and persistency of atopic dermatitis among different demographics, said Jonathan Silverberg, MD, PhD, MPH.

Asthma exacerbations among Black/African American and Hispanic/Latinx adults with moderate-to-severe asthma decreased by approximately 40% during the COVID-19 pandemic, particularly among individuals who worked outside the home and those without type 2 inflammation.

Dupilumab is effective for atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps, but a recent presentation noted the payer challenge in placing the biologic in an optimal tier.

As the population continues to diversify, the United States may be headed for increases in atopic dermatitis disease burden among children, said Jonathan Silverberg, MD, PhD, MPH.

As atopic dermatitis (AD) prevalence has increased in children over several decades, it's critical for physicians to recognize the environmental and demographic factors contributing to the change, said Jonathan Silverberg, MD, PhD, MPH.

The study findings show that atopic dermatitis is associated with internalizing and externalizing problems, with younger children experiencing emotional problems and adolescents with other atopic diseases having relationship problems.

Data from a recent cross-sectional study show severity of atopic dermatitis (AD) is associated with prevalence of learning disorders among children.

According to the researchers, the study is the first to describe a relationship between these factors and the development of atopic dermatitis (AD) in infants using multiomics.

Exposure to indoor formaldehyde can exacerbate atopic dermatitis (AD) symptoms in children with moderate to severe disease, especially in spring and summer and even at allowable levels.

Machine learning models can help predict which children diagnosed with childhood asthma before age 5 will continue to experience symptoms as they get older.

Deep learning algorithms to diagnose skin disease like atopic dermatitis could save time for providers while increasing accuracy, according to a pilot study.

Recent findings indicate that the symptoms of atopic dermatitis, hives, and rhinitis can all be linked to specific microbiota, implying that the gut-skin axis and gut-nose axis do exist.

The case illustrates how these 2 different conditions may share a related mechanism of action.

Although 90% of patients with severe asthma choose to continue using a biologic, patients with worse disease control at baseline or with lower socioeconomic status (SES) may be more likely to cease biologic use, according to a poster presented at the American Academy of Allergy, Asthma & Immunology 2021 Annual Meeting.

Use of a specialty pharmacy to take over the management of prior authorization (PA) requests for a dermatology practice significantly reduced the time to a decision and also decreased the time it took to fill the medication.

Treatment of asthma with biologics was lower for those on public health insurance compared with those who had private insurance, with Blacks underrepresented relative to Whites in publicly insured visits where biologic treatment is used.